The stock of Harpoon Therapeutics Inc (HARP) has gone up by 80.25% for the week, with a 96.39% rise in the past month and a 46.28% rise in the past quarter. The volatility ratio for the week is 16.48%, and the volatility levels for the past 30 days are 14.42% for HARP. The simple moving average for the past 20 days is 85.32% for HARP’s stock, with a 61.49% simple moving average for the past 200 days.

Is It Worth Investing in Harpoon Therapeutics Inc (NASDAQ: HARP) Right Now?

, and the 36-month beta value for HARP is at 1.92. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.


The average price suggested by analysts for HARP is $14.10, which is $2.69 above the current market price. The public float for HARP is 13.41M, and currently, shorts hold a 1.78% of that float. The average trading volume for HARP on November 20, 2023 was 133.01K shares.

HARP) stock’s latest price update

Harpoon Therapeutics Inc (NASDAQ: HARP)’s stock price has gone rise by 21.00 in comparison to its previous close of 9.43, however, the company has experienced a 80.25% increase in its stock price over the last five trading days. Zacks Investment Research reported 2023-11-15 that Harpoon Therapeutics, Inc. (HARP) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our ‘Fast-Paced Momentum at a Bargain’ screen.

Analysts’ Opinion of HARP

Many brokerage firms have already submitted their reports for HARP stocks, with Canaccord Genuity repeating the rating for HARP by listing it as a “Buy.” The predicted price for HARP in the upcoming period, according to Canaccord Genuity is $16 based on the research report published on July 06, 2022 of the previous year 2022.

HARP Trading at 117.03% from the 50-Day Moving Average

After a stumble in the market that brought HARP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.99% of loss for the given period.

Volatility was left at 14.42%, however, over the last 30 days, the volatility rate increased by 16.48%, as shares surge +65.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +46.28% upper at present.

During the last 5 trading sessions, HARP rose by +80.25%, which changed the moving average for the period of 200-days by +11.86% in comparison to the 20-day moving average, which settled at $6.38. In addition, Harpoon Therapeutics Inc saw 57.23% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at HARP starting from HUNT RONALD, who purchase 10,000 shares at the price of $1.00 back on Mar 23. After this action, HUNT RONALD now owns 10,000 shares of Harpoon Therapeutics Inc, valued at $10,000 using the latest closing price.

Stock Fundamentals for HARP

Current profitability levels for the company are sitting at:

The net margin for Harpoon Therapeutics Inc stands at -212.22. The total capital return value is set at -149.08, while invested capital returns managed to touch -154.65. Equity return is now at value -284.33, with -46.54 for asset returns.

Based on Harpoon Therapeutics Inc (HARP), the company’s capital structure generated 296.46 points at debt to equity in total, while total debt to capital is 74.78. Total debt to assets is 21.71, with long-term debt to equity ratio resting at 251.58. Finally, the long-term debt to capital ratio is 63.46.

When we switch over and look at the enterprise to sales, we see a ratio of 4.18, with the company’s debt to enterprise value settled at -1.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.04.


In conclusion, Harpoon Therapeutics Inc (HARP) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.